Locoregional Therapy: From Mastectomy to Reconstruction, Targeted Surgery and ultra-hypofractionated Radiotherapy

被引:0
|
作者
Banys-Paluchowski, Maggie [1 ]
Hartmann, Steffi [2 ]
Ditsch, Nina [3 ]
Krawczyk, Natalia [4 ]
Kuehn, Thorsten [5 ]
de Boniface, Jana [6 ,7 ]
Banys-Kotomska, Joanna [8 ]
Rody, Achim [9 ]
Krug, David [10 ]
机构
[1] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany
[2] Univ Hosp Rostock, Dept Gynecol & Obstet, Rostock, Germany
[3] Univ Hosp Augsburg, Breast Canc Ctr, Dept Gynaecol & Obstet, Augsburg, Germany
[4] Heinrich Heine Univ Dusseldorf, Dept Gynecol & Obstet, Dusseldorf, Germany
[5] Filderklin, Dept Gynecol & Obstet, D-70794 Filderstadt, Germany
[6] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[7] Capio St Gorans Hosp, Dept Surg, Stockholm, Sweden
[8] Wroclaw Med Univ, Dept & Clin Gynaecol & Obstet 1, Wroclaw, Poland
[9] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Campus Lubeck, Lubeck, Germany
[10] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Campus Kiel, Kiel, Germany
关键词
Breast cancer; partial breast irradiation; breast-conserving therapy; targeted axillary dissection; localization method; LYMPH-NODE BIOPSY; STAGE BREAST-CANCER; 20-YEAR FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY; CONSERVING SURGERY; NON-INFERIORITY; SENTINEL NODE; AGO RECOMMENDATIONS; RADICAL-MASTECTOMY; SYSTEMIC THERAPY;
D O I
10.1159/000533748
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The past three decades have seen an unprecedented shift towards treatment de-escalation in surgical therapy of breast cancer.Summary: Radical mastectomy has been replaced by breast-conserving and oncoplastic approaches in most patients, and full axillary lymph node dissection by less radical staging procedures, such as sentinel lymph node biopsy and targeted axillary dissection. Further, attempts have been made to spare healthy tissue while increasing the probability of removing the tumor with clear margins, thus improving cosmetic results and minimizing the risk of local recurrence. In this context, modern probe-guided localization techniques have been introduced to guide surgical excision. This progress was accompanied by the development of targeted systemic therapies. At the same time, radiotherapy for breast cancer has undergone significant changes. The use of hypofractionation has decreased the typical length of a treatment course from 5-6 weeks to 1-3 weeks. Partial breast irradiation is now a valid option for de-escalation in patients with low-risk features. Axillary radiotherapy achieves similar recurrence rates and decreases the risk of lymphedema in patients with limited sentinel node involvement.Key messages: Taken together, these advances are important steps towards individualization of locoregional management strategies. This highlights the importance of interdisciplinary approaches for de-escalation of locoregional therapies.
引用
收藏
页码:428 / 439
页数:12
相关论文
共 50 条
  • [1] Weekly ultra-hypofractionated radiotherapy in localised prostate cancer
    Sundahl, Nora
    Brand, Douglas
    Parker, Chris
    Dearnaley, David
    Tree, Alison
    Pathmanathan, Angela
    Suh, Yae-eun
    Van As, Nicholas
    Eeles, Rosalind
    Khoo, Vincent
    Huddart, Robert
    Murray, Julia
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 47
  • [2] Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results
    Ratosa, Ivica
    Montero, Angel
    Ciervide, Raquel
    Alvarez, Beatriz
    Garcia-Aranda, Mariola
    Valero, Jeannette
    Xin, Chen-Zhao
    Lopez, Mercedes
    Zucca, Daniel
    Hernando, Ovidio
    Sanchez, Emilio
    de la Casa, Miguel Angel
    Alonso, Rosa
    Fernandez-Leton, Pedro
    Rubio, Carmen
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 46
  • [3] Ultra-hypofractionated radiotherapy in High risk localised prostate cancer
    Colom Pla, Claudia
    Navarro Aznar, Victoria
    Garcia Aguilera, Cristina
    Cerrolaza Pascual, Maria
    Lanuza Carnicer, Alberto
    Galan Garcia, Ana
    Mendez Villamon, Agustina
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2568 - S2569
  • [4] Moderate versus ultra-hypofractionated locoregional breast radiotherapy: Results of a retrospective study during the covid-19 era
    Rivera, Paola Andrea
    Yeo, Anne-Emmanuella
    Dhenin, Arnaud
    Bodson, Elisa
    Brahy, Eleonore
    Stokart, Julinne
    Donnay, Lorraine
    Seret, Monique
    Vanderick, Jean
    Bihin, Benoit
    Regnier, Maxime
    Remouchamps, Vincent
    CANCER RADIOTHERAPIE, 2025, 29 (01):
  • [5] Toxicity, Dosimetric & Survival analysis of Ultra-Hypofractionated Radiotherapy for Breast Cancer
    Dandekar, Prasad Raj
    Gupte, Ajinkya
    Kadam, Rohan
    Kakade, Amol
    Dhoundiyal, Mayank
    Shaikh, Naseem
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S714 - S716
  • [6] Implementation of ultra-hypofractionated radiotherapy in early breast cancer: economic impact
    Mateu Castell, Luis
    Gadea Quinteiro, Jon
    Garcia Zanoguera, Carlos
    Curbelo Artiles, Alba G.
    Grau Morenilla, Andrea
    Llabres Busch, Gemma V.
    Ortiz Gonzalez, Irene
    Mestre Meste, Francisco J.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2839 - S2841
  • [7] Ultra-Hypofractionated Prostate Radiotherapy With Online Adaptive Technique: A Case Report
    Yoganathan, S. A.
    Riyas, Mohamed
    Sukumaran, Renilmon
    Hammoud, Rabih
    Al-Hammadi, Noora
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [8] Ultra-hypofractionated radiotherapy for breast cancer : Dosecontraints on the controlateral breast are warranted
    Ben Rejeb, M.
    Abdessattar, G.
    Ghorbel, S.
    Mezghani, M.
    Ghorbal, L.
    Kochbati, L.
    BREAST, 2025, 80
  • [9] Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer
    Oehler, Christoph
    Roehner, Nina
    Sumila, Marcin
    Curschmann, Juergen
    Storelli, Fabrizio
    Zwahlen, Daniel Rudolf
    Schneider, Uwe
    CURRENT ONCOLOGY, 2022, 29 (09) : 6314 - 6324
  • [10] Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer
    Ozyigit, Gokhan
    Onal, Cem
    Esen, Caglayan Selenge Beduk
    Tilki, Burak
    Hurmuz, Pervin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 252.e1 - 252.e8